02 May 2003
Regulation of microglial functions by PARP-1 – a target for therapeutic interventions?
O. UllrichMed Sci Monit 2003; 9(1): 73-0 :: ID: 15216
Abstract
During the last decade of neurobiological research, it has become evident that inflammatory pathways in the CNS, involving a network of non-neuronal and neuronal cells, are important contributors to the onset and progress of several major neurodegenerative diseases [1]. One major component of inflammatory neuronal damage is the transformation of microglia cells into activated immunoeffector cells and their migration towards the sites of injury, where they produce large amounts of toxic cytokines and oxygen radicals [2]. During this transformation, PARP-1 is highly activated and enables microglia cells to cope with oxidative challenges, in particular by upregulating the proteasomal degradation of damaged nuclear proteins [3]. Besides the initiation of intracellular defense pathways, PARP-1-dependent signalling is also involved in regulating specific functions of activated microglia: It regulates the expression of the integrin CD11a through interaction with the translocated NF-kB and therefore strongly controls migration into the regions of neuronal injury [4]. Furthermore, it enhances the production of the proinflammatory cytokine TNF-alpha and of the antiinflammatory endocannabinoid 2-AG, which in turn downregulates the release of nitric oxide. We are therefore considering PARP-1 to be a multiple player in the concert of neuroinflammation, in which therapeutic interventions directed against PARP-1 would affect both neuronal and non-neuronal components. Downregulation of PARP-1 specifically in microglia almost completely abrogates microglial migration and prevents neurons from secondary damage. This renders PARP-1 a target for therapeutic strategies in neurodegenerative diseases, in which pathological microglia activation and migration play a major role. References: 1.Floyd RA et al: Free Radic Biol Med, 1999; 26: 1346-1355 2.Mabuchi T et al: Stroke, 2000; 31(7): 1735-1743 3.McGeer PL et al: Brain Res Rev, 1995; 21: 195-218 4.Ullrich O et al: FASEB J, 2001; 15: 1460-1462 5.Ullrich O et al: Nature Cell Biol, 2001; 3: 1035-1042
Keywords: neuroinflammation, Microglia, Cytokines, Integrins
Editorial
01 April 2025 : Editorial
Editorial: Rapid Testing for the Avian Influenza A(H5N1) Virus is Urgently Required as Infections in Poultry and Dairy Cows are on the Rise, and so is Transmission to HumansDOI: 10.12659/MSM.949109
Med Sci Monit 2025; 31:e949109
In Press
Clinical Research
Use of The Mirror-Image Technique for Patient-Specific Reconstruction of Cuboid FracturesMed Sci Monit In Press; DOI: 10.12659/MSM.947437
Laboratory Research
Retention of 3-D-Printed, Milled, and Conventionally Fabricated Occlusal SplintsMed Sci Monit In Press; DOI: 10.12659/MSM.947342
Review article
A Review of Circulating Tumor DNA (ctDNA) and the Liquid Biopsy in Cancer Diagnosis, Screening, and Monitor...Med Sci Monit In Press; DOI: 10.12659/MSM.949300
Clinical Research
Buccal Acupuncture Reduces the Dose of Sufentanil Needed in Laparoscopic Gynecological SurgeryMed Sci Monit In Press; DOI: 10.12659/MSM.947088
Most Viewed Current Articles
17 Jan 2024 : Review article 7,932,846
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,905
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 29,808
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 23,790
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912